We found for
When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
How is Quality of Life Measured for Health Technology Assessments?
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
